Next Generation Sequencing Market Size, Share, Growth, and Industry Analysis, By Type (Ion semiconductor sequencing, Sequencing by the synthesis (SBS), Nanopore sequencing, Single-molecule real-time (SMRT) sequencing), By Application (Biotechnology and Pharmaceutical Companies, Research Centres, Hospitals & Clinics, Others), Regional Insights and Forecast to 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

NEXT GENERATION SEQUENCING MARKET OVERVIEW

The global Next Generation Sequencing Market size estimated at USD 24.68 billion in 2026 and is projected to reach USD 119.78 billion by 2035, growing at a CAGR of 19.19% from 2026 to 2035.

The Next Generation Sequencing Market has become a critical component of modern genomics, supporting large-scale DNA and RNA analysis across research, diagnostics, oncology, and precision medicine applications. More than 40 million human genomes had been sequenced globally by 2025, creating strong demand for advanced sequencing platforms and bioinformatics tools. Sequencing by Synthesis technology accounted for 38.1% of technology adoption in 2025, while North America represented 44.7% of global market activity. Clinical sequencing tests exceeded 12 million annually worldwide, supported by growing cancer screening programs. More than 8,500 genomic laboratories currently utilize next generation sequencing systems for disease identification and therapeutic development.

The United States remains the largest contributor to the Next Generation Sequencing Market, supported by extensive genomic research programs and advanced healthcare infrastructure. More than 3,500 clinical laboratories in the country perform sequencing-based testing, while over 1.8 million cancer cases are diagnosed annually, creating substantial demand for genomic profiling. The National Institutes of Health supports thousands of genomics projects every year, and over 70% of precision oncology programs in major hospitals integrate sequencing technologies. More than 400 biotechnology companies in the U.S. actively employ next generation sequencing for biomarker discovery, drug development, and rare disease analysis, strengthening market penetration nationwide.

KEY FINDINGS

LATEST TRENDS

The Next Generation Sequencing Market is experiencing rapid transformation through automation, artificial intelligence integration, and long-read sequencing technologies. More than 66% of genomic laboratories adopted AI-assisted data interpretation platforms during 2025, significantly improving variant detection accuracy. Single-cell sequencing usage increased across over 52% of advanced research centers, enabling detailed cellular profiling in oncology and immunology studies. Long-read sequencing technologies now account for approximately 18% of genomic workflows, driven by increasing demand for structural variant analysis.

Cancer genomics remains the largest application area, representing nearly 50% of sequencing-based clinical investigations. More than 12 million sequencing tests are conducted annually worldwide for oncology, hereditary disease screening, and infectious disease monitoring. Cloud-based genomic analysis platforms support approximately 45% of sequencing laboratories, reducing computational infrastructure requirements. Portable sequencing devices have expanded field-based genomic testing by 31%, particularly in infectious disease surveillance and environmental monitoring.

MARKET DYNAMICS

Driver

Rising demand for precision medicine and oncology diagnostics.

Precision medicine has become one of the strongest growth drivers for the Next Generation Sequencing Market. More than 1.8 million cancer cases are diagnosed annually in the United States alone, creating substantial demand for genomic profiling. Approximately 72% of precision oncology programs rely on sequencing technologies for mutation identification and treatment selection. More than 60% of targeted drug development projects utilize sequencing during biomarker discovery stages. Worldwide, over 40 million genomes have been sequenced, supporting advancements in disease prediction and personalized therapy.

Restraint

High equipment costs and complex data analysis requirements.

Despite technological advancements, sequencing implementation remains expensive for many institutions. High-throughput sequencing instruments often require specialized laboratory infrastructure and advanced computational resources. Approximately 47% of healthcare facilities identify capital investment requirements as a major barrier. Around 39% of laboratories report shortages of trained bioinformatics professionals capable of handling genomic datasets. A single sequencing run can generate terabytes of data, increasing storage and processing demands.

Expansion of genomic testing in emerging healthcare systems

Opportunity

Emerging economies are increasingly investing in genomic medicine infrastructure. More than 20 national genome initiatives are currently active worldwide, supporting population-scale sequencing projects. India, China, South Korea, and several Middle Eastern countries continue expanding genomic research programs.

Approximately 55% of new sequencing laboratory installations occur within Asia-Pacific healthcare and research institutions. Infectious disease surveillance programs have increased sequencing deployment by 42% across public health organizations.

Managing large genomic datasets and regulatory compliance

Challenge

The genomic data generated through next generation sequencing continues to increase substantially each year. More than 70% of sequencing laboratories identify data management as a significant operational challenge. Large genome sequencing projects can produce petabytes of information requiring secure storage and processing infrastructure.

Approximately 41% of healthcare organizations report difficulties integrating genomic results into electronic medical records. Regulatory requirements for genetic data protection continue expanding globally, affecting laboratory workflows.

•   
•   
  

  Download Free Sample to learn more about this report

    

NEXT GENERATION SEQUENCING MARKET SEGMENTATION

By Type

• Ion Semiconductor Sequencing: Ion semiconductor sequencing maintains a significant position within the Next Generation Sequencing Market due to rapid sequencing speed and reduced workflow complexity. The technology accounts for approximately 17% of technology utilization globally. More than 2,000 laboratories employ ion semiconductor platforms for targeted oncology panels and microbial sequencing applications. The technology offers sequencing runs within several hours, supporting faster clinical decision-making. Nearly 45% of users implement ion semiconductor systems for genetic disease screening.

• Sequencing by the Synthesis (SBS): Sequencing by the Synthesis dominates the global Next Generation Sequencing Market with approximately 38.1% technology share. The technology is extensively used across research institutions, pharmaceutical companies, and clinical laboratories. More than 70% of large-scale genome projects employ SBS platforms due to high accuracy and scalability. Thousands of sequencing laboratories utilize SBS systems for whole genome sequencing, transcriptomics, and oncology applications. The technology supports billions of sequencing reads per run, making it suitable for population genomics studies.

• Nanopore Sequencing: Nanopore sequencing continues gaining market momentum and accounts for approximately 21% of sequencing technology utilization. The technology enables real-time sequencing and portable genomic analysis. More than 120 countries have adopted nanopore systems for infectious disease surveillance and environmental genomics. Portable sequencing devices weigh less than 500 grams and can operate outside conventional laboratories. Approximately 48% of field-based genomic projects utilize nanopore sequencing because of mobility advantages.

• Single-Molecule Real-Time (SMRT) Sequencing: Single-Molecule Real-Time sequencing represents approximately 14% of technology adoption and remains essential for long-read genomic analysis. The technology can generate read lengths exceeding 20,000 base pairs, supporting structural variation analysis and complex genome assembly. More than 1,500 research facilities worldwide utilize SMRT sequencing systems. Approximately 55% of advanced genomic studies involving repetitive DNA regions employ long-read sequencing technologies. Pharmaceutical companies increasingly use SMRT sequencing for transcriptome characterization and biomarker discovery.

By Application

• Biotechnology and Pharmaceutical Companies: Biotechnology and pharmaceutical companies represent approximately 34% of Next Generation Sequencing Market demand. More than 60% of drug discovery programs utilize sequencing technologies for target identification and biomarker validation. Pharmaceutical organizations conduct over 100,000 sequencing-based studies annually worldwide. Approximately 58% of oncology drug development projects depend on genomic analysis for patient stratification. Sequencing supports companion diagnostic development, clinical trial optimization, and precision medicine initiatives.

• Research Centres: Research centers account for approximately 31% of sequencing utilization globally. More than 45% of sequencing activity originates from academic and research institutions conducting genome mapping, transcriptomics, and disease biology studies. Thousands of government-funded genomics projects utilize next generation sequencing annually. Research institutions contribute significantly to advancements in single-cell sequencing, metagenomics, and population genomics. Approximately 52% of published genomics studies involve NGS-generated datasets.

• Hospitals & Clinics: Hospitals and clinics contribute approximately 25% of market demand through clinical sequencing applications. More than 4,000 hospitals worldwide operate genomic medicine programs integrating sequencing technologies into patient care. Oncology testing represents nearly 50% of hospital sequencing utilization. Approximately 68% of precision medicine centers employ genomic profiling for cancer diagnosis and treatment planning. Clinical sequencing is increasingly utilized for hereditary disease screening, prenatal testing, and infectious disease detection.

• Others: The other applications segment contributes approximately 10% of market activity and includes public health laboratories, agricultural genomics organizations, forensic institutions, and environmental monitoring agencies. More than 120 national public health programs utilize sequencing for pathogen surveillance and outbreak tracking. Agricultural genomics projects increasingly employ sequencing technologies for crop improvement and livestock breeding. Approximately 35% of microbial ecology studies utilize sequencing-based approaches for biodiversity analysis.

•   
•   
  Download Free Sample to learn more about this report

    

NEXT GENERATION SEQUENCING MARKET REGIONAL OUTLOOK

• North America

North America represents approximately 44.7% of the global Next Generation Sequencing Market. The United States accounts for the majority of regional activity, supported by advanced healthcare systems and large-scale genomics initiatives. More than 3,500 clinical laboratories perform sequencing-based testing throughout the region. Approximately 72% of precision oncology programs integrate genomic profiling into treatment planning.

Over 1.8 million annual cancer diagnoses contribute significantly to sequencing demand. National genome projects and research funding continue supporting technological advancement. More than 400 biotechnology companies actively utilize sequencing for drug development and biomarker discovery. Clinical sequencing adoption exceeds 65% among major academic medical centers.

• Europe

Europe accounts for approximately 28.4% of global Next Generation Sequencing Market activity. Countries including Germany, the United Kingdom, France, and the Netherlands continue investing heavily in genomic medicine and precision healthcare programs. More than 2,500 genomic research facilities operate throughout the region.

Approximately 58% of European cancer research programs employ sequencing technologies for molecular profiling. Several national genome initiatives collectively target millions of genomic samples for disease research and personalized medicine implementation. Clinical sequencing adoption has increased significantly among tertiary healthcare institutions.

• Asia-Pacific

Asia-Pacific holds approximately 21.9% of the Next Generation Sequencing Market and represents one of the fastest-expanding regions for genomic technologies. China, Japan, India, South Korea, and Australia continue increasing investments in genomics infrastructure. More than 55% of new sequencing laboratory installations are located within Asia-Pacific countries.

Large population bases and growing healthcare expenditure support increasing genomic testing demand. China operates extensive national genome programs involving millions of participants. India continues expanding precision medicine initiatives and genomic research capabilities. More than 2,000 research organizations across the region employ next generation sequencing technologies.

• Middle East & Africa

Middle East and Africa contribute approximately 5.0% of global Next Generation Sequencing Market activity. Despite a smaller share, the region demonstrates increasing investment in genomic medicine and population health initiatives. Several Gulf countries have launched national genome programs involving hundreds of thousands of participants.

Precision medicine adoption continues expanding across specialized healthcare institutions. More than 300 genomic laboratories currently operate throughout the region. Approximately 40% of advanced healthcare centers have integrated sequencing-based diagnostic capabilities. Cancer genomics and hereditary disease screening represent major application areas.

LIST OF TOP NEXT GENERATION SEQUENCING COMPANIES

• Illumina, Inc.
• Thermo Fisher Scientific, Inc.
• BGI Group
• PerkinElmer Inc.
• Macrogen
• Hamilton Company
• Lucigen
• Intrexon Bioinformatics GmbH
• Partek Incorporated
• DNASTAR, Inc.
• DNAnexus
• SciGenom Labs Pvt. Ltd.
• GENEWIZ
• Takara Bio Inc.
• Becton Dickinson and Company
• Danaher
• Lexogen GmbH
• Tecan Trading AG
• Zymo Research
• Oxford Nanopore Technologies
• Agilent Technologies, Inc.
• QIAGEN

List Of Top 2 Companies Market Share

• Illumina, Inc. holds approximately 70% of global next generation sequencing platform deployment, supported by extensive use of NovaSeq, NextSeq, and MiSeq systems across research and clinical laboratories.
• Thermo Fisher Scientific, Inc. accounts for nearly 15% market participation, driven by broad adoption of Ion Torrent sequencing technologies and integrated genomic workflow solutions.

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment activity within the Next Generation Sequencing Market continues increasing due to growing precision medicine adoption and expanding genomic research programs. More than 20 national genome initiatives worldwide are currently supported through public and private investments. Over 55% of biotechnology investors prioritize genomics-related technologies because of increasing demand for molecular diagnostics and personalized therapies.

Pharmaceutical companies allocate substantial research budgets toward sequencing-enabled drug discovery, with more than 60% of oncology development pipelines utilizing genomic biomarkers. Clinical sequencing infrastructure investments have increased across hospitals, diagnostic laboratories, and academic institutions. More than 4,000 hospitals globally now operate precision medicine programs integrating genomic testing.

NEW PRODUCT DEVELOPMENT

Product innovation remains a central competitive strategy within the Next Generation Sequencing Market. Manufacturers continue introducing higher-throughput instruments capable of processing billions of sequencing reads within a single workflow. More than 58% of newly launched sequencing systems focus on throughput enhancement and reduced turnaround times.

Artificial intelligence integration has become a major innovation area, with approximately 49% of new product launches featuring automated variant interpretation capabilities. Advanced long-read sequencing systems continue improving read lengths beyond 20,000 base pairs, supporting complex genomic analyses. Portable sequencing devices now support real-time genomic monitoring in clinical, environmental, and public health applications.

FIVE RECENT DEVELOPMENTS (2023-2025)

• In 2025, Illumina expanded adoption of NovaSeq X platforms, improving sequencing throughput by more than 2.5 times compared with several earlier-generation systems.
• In 2025, Oxford Nanopore Technologies enhanced long-read sequencing performance, enabling read lengths exceeding 20,000 base pairs across advanced genomic workflows.
• In 2024, Thermo Fisher Scientific expanded Ion Torrent sequencing solutions with improved automation capabilities supporting higher laboratory productivity.
• In 2024, BGI strengthened large-scale genomic sequencing capacity, supporting population genomics initiatives involving millions of genomic samples.
• In 2023, Agilent Technologies introduced advanced genomic sample preparation solutions that improved sequencing workflow efficiency by approximately 30% in high-volume laboratories.

NEXT GENERATION SEQUENCING MARKET REPORT COVERAGE

The Next Generation Sequencing Market report provides detailed evaluation of technology platforms, applications, end users, competitive positioning, and regional performance. The analysis covers Ion semiconductor sequencing, Sequencing by Synthesis, nanopore sequencing, and Single-Molecule Real-Time sequencing technologies. More than 20 countries are assessed to evaluate adoption patterns, healthcare infrastructure, and genomic research activities.

The report examines biotechnology and pharmaceutical companies, research centers, hospitals and clinics, and additional end-user categories. It includes assessment of genomic testing demand, cancer diagnostics utilization, rare disease applications, and infectious disease surveillance activities. Approximately 40 million sequenced genomes and over 12 million annual sequencing tests provide important market indicators.